US pharma giant is unhappy with Germany; CEO calls planned healthcare reform ‘terrible’
US drug maker Eli Lilly is cutting its investment in a German factory by half. This decision follows new healthcare cost-cutting laws in Germany. The company CEO called the reforms a bad signal for the industry. This move impacts Germany's industrial plans. The factory will now operate at reduced capacity with fewer jobs. Other companies are also reconsidering local investments.المصدر: Times of India | Source: Times of India
ملاحظة تحريرية | Editorial Note: نُشر هذا المقال في الأصل بواسطة Times of India. خبر (Khabr) هي منصة إعلامية أردنية مرخّصة تعمل بالذكاء الاصطناعي. نضيف قيمة تحريرية من خلال: تحليل ذكي للأخبار، ملخصات تلقائية، رواية صوتية بالذكاء الاصطناعي، ترجمة متعددة اللغات، وتدقيق الحقائق. هدفنا جعل الأخبار أكثر وضوحاً وسهولةً للقارئ العربي.
This article was originally published by Times of India. Khabr is a licensed Jordanian AI-powered news platform (Registration #82086). We add editorial value through: AI-powered news analysis, automated summaries, AI audio narration, multi-language translation (Arabic, English, French, Turkish), and AI fact-checking. Our mission is to make news more accessible and understandable for Arabic-speaking audiences worldwide.
